381 related articles for article (PubMed ID: 28452992)
1. Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema.
Nicholson L; Patrao NV; Ramu J; Vazquez-Alfageme C; Muwas M; Rajendram R; Hykin PG; Sivaprasad S
Eye (Lond); 2017 Sep; 31(9):1358-1364. PubMed ID: 28452992
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
Laugesen CS; Ostri C; Brynskov T; Lund-Andersen H; Larsen M; Vorum H; Sørensen TL
Acta Ophthalmol; 2017 Feb; 95(1):28-32. PubMed ID: 27473397
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.
Ebneter A; Wolf S; Zinkernagel MS
Br J Ophthalmol; 2016 Mar; 100(3):365-70. PubMed ID: 26187951
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
Campochiaro PA; Khanani A; Singer M; Patel S; Boyer D; Dugel P; Kherani S; Withers B; Gambino L; Peters K; Brigell M;
Ophthalmology; 2016 Aug; 123(8):1722-1730. PubMed ID: 27236272
[TBL] [Abstract][Full Text] [Related]
5. Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.
Wong Y; Steel DHW; Habib MS; Stubbing-Moore A; Bajwa D; Avery PJ;
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):733-742. PubMed ID: 27957600
[TBL] [Abstract][Full Text] [Related]
6. Classification of diabetic macular oedema using ultra-widefield angiography and implications for response to anti-VEGF therapy.
Xue K; Yang E; Chong NV
Br J Ophthalmol; 2017 May; 101(5):559-563. PubMed ID: 27531355
[TBL] [Abstract][Full Text] [Related]
7. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
Pieramici DJ; Wang PW; Ding B; Gune S
Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
[TBL] [Abstract][Full Text] [Related]
8. Diameter of retinal vessels in patients with diabetic macular edema is not altered by intravitreal ranibizumab (lucentis).
Terai N; Haustein M; Siegel A; Stodtmeister R; Pillunat LE; Sandner D
Retina; 2014 Jul; 34(7):1466-72. PubMed ID: 24457978
[TBL] [Abstract][Full Text] [Related]
9. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.
Baget-Bernaldiz M; Romero-Aroca P; Bautista-Perez A; Mercado J
Doc Ophthalmol; 2017 Oct; 135(2):85-96. PubMed ID: 28779336
[TBL] [Abstract][Full Text] [Related]
10. RETINAL LAYER RESPONSE TO RANIBIZUMAB DURING TREATMENT OF DIABETIC MACULAR EDEMA: Thinner is Not Always Better.
Ebneter A; Wolf S; Abhishek J; Zinkernagel MS
Retina; 2016 Jul; 36(7):1314-23. PubMed ID: 26735563
[TBL] [Abstract][Full Text] [Related]
11. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy.
Mikhail M; Stewart S; Seow F; Hogg R; Lois N
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188
[TBL] [Abstract][Full Text] [Related]
12. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
13. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
Okamoto M; Yamashita M; Ogata N
Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
[TBL] [Abstract][Full Text] [Related]
15. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
[TBL] [Abstract][Full Text] [Related]
16. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
Nepomuceno AB; Takaki E; Paes de Almeida FP; Peroni R; Cardillo JA; Siqueira RC; Scott IU; Messias A; Jorge R
Am J Ophthalmol; 2013 Sep; 156(3):502-510.e2. PubMed ID: 23795985
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections.
Kim M; Cho YJ; Lee CH; Lee SC
Eye (Lond); 2016 May; 30(5):718-25. PubMed ID: 26939558
[TBL] [Abstract][Full Text] [Related]
20. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
